Adicet Bio, Inc is a pharmaceutical company based in the United States that specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases. With an ESG score of 26.6, the company is considered to have a medium risk assessment. Their lead product candidate, ADI-001, is a first-in-class allogeneic gamma delta T cell therapy designed for autoimmune diseases and aggressive B cell non-Hodgkin's lymphoma. Adicet Bio's pipeline also includes a preclinical candidate, ADI-270, which targets renal cell carcinoma and other solid tumor and hematological malignancies.